Biotech Stocks Reviews
- Lack of Clarity Continues Pushing Affimed Lower
Fri, Mar 24
Affimed announced a rather disappointing update yesterday. There was not much clarity shared and it · more » - Karuna Latest Phase 3 Data Strengthens Upcoming NDA
Tue, Mar 21
Yesterday Karuna (KRTX) reported data on the third positive registrational trial, announcing that the · more » - Government Steps In To Save Depositors, Many Bio Companies
Tue, Mar 14
The wild weekend was followed by an eventful Monday, especially for the biotech world. The SVB fiasco · more » - Silicon Valley Bank (SVB) Collpase Impacts Bio Markets
Tue, Mar 14
Silicon Valley Banks collapse has caused a ripple amongst the biotech world as the bank did business · more » - Day One (DAWN) To Present Updated Results Ahead of NDA Submission
Fri, Mar 3
Day One’s Drug Ready for NDADay One Pharma (DAWN) is developing tovorafenib (DAY101), an oral pan-RAF · more » - aTyr (LIFE) Financing Makes It Late 2023 Story
Fri, Feb 10
aTyr(LIFE) announced a financing yesterday which diluted the company by approximately 45%. LIFE offered · more » - Addex Gives Vague Update on Q1 Data Readout
Mon, Feb 6
This morning, Addex (ADXN) announced that Janssen has completed the enrolment of Part 1 of their Phase 2 · more » - 2023 Names & Themes To Watch
Thu, Jan 19
Below are a few names to watch, each divided into a different segment. Value: Atyr Pharma (LIFE)Atyr · more » - NK Sentiment and Impact on Affimed
Mon, Jan 9
Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the · more »